Sodium and potassium and the pathogenesis of hypertension

Current Hypertension Reports

Volumn 15, Issue 2, 2013, Pages 122-130

  Stolarz Skrzypek, Katarzyna ^a   Bednarski, Adam ^a   Czarnecka, Danuta ^a   Kawecka Jaszcz, Kalina ^a   Staessen, Jan A ^b,c  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^b UNIVERSITY OF LEUVEN   (Belgium)

^c MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

Blood pressure; Cardiovascular mortality; Cardiovascular outcomes; Hypertension; Potassium; Salt; Sodium

Indexed keywords

POTASSIUM; POTASSIUM CHANNEL; RAMIPRIL; SODIUM; TELMISARTAN;

BLOOD PRESSURE REGULATION; DIETARY INTAKE; DISEASE ASSOCIATION; EVIDENCE BASED MEDICINE; FOOD FREQUENCY QUESTIONNAIRE; FRUIT; HUMAN; HYPERTENSION; MEDICAL SOCIETY; META ANALYSIS (TOPIC); MORBIDITY; MORTALITY; NONHUMAN; OUTCOME ASSESSMENT; PATHOGENESIS; POTASSIUM URINE LEVEL; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; SALT INTAKE; SODIUM RESTRICTION; SODIUM RETENTION; SODIUM URINE LEVEL; URINALYSIS; VEGETABLE;

BLOOD PRESSURE; HUMANS; HYPERTENSION; POTASSIUM, DIETARY; SODIUM, DIETARY;

EID: 84879605555     PISSN: 15226417     EISSN: 15343111     Source Type: Journal    
DOI: 10.1007/s11906-013-0331-x     Document Type: Review

References (63)

1. Robertson JIS. Dietary salt and hypertension: a scientific issue or a matter of faith? J Eval Clin Pract. 2003;9:1-22.
2. Alderman MH. Reducing dietary sodium. The case for caution. JAMA. 2010;303:448-9.
3. Anonymous. Salt and cardiovascular disease mortality. Lancet. 2011;377:1626.
4. Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360:1903-13.
5. Geerling JC, Loewy AD. Central regulation of sodium appetite. Exp Physiol. 2008;93:177-209.
6. Guyton AC. Long-term arterial pressure control: an analysis from animal experiments and computer and graphic models. Am J Phys. 1990;259:R865-77.
7. Visser FW, Boonstra AH, Titia Lely A, Boomsma F, Navis G. Renal response to angiotensin II is blunted in sodium-sensitive men. Am J Hypertens. 2008;21:323-8.
8. Luft FC. Molecular aspects of genetics of salt-sensitivity and hypertension. Drug Metab Dispos. 2003;29:500-4.
9. Staessen JA, Wang J, Bianchi G, Birkenhäger WH. Essential hypertension. Lancet. 2003;361:1629.
10. Beretta-Piccoli C, Weidmann P, Brown JJ, Davies DL, Lever AF, Robertson JIS. Body sodium and blood volume state in essential hypertension: abnormal relation of exchangeable sodium to age and blood pressure in male patients. J Cardiovasc Pharmacol. 1984;6(suppl 1):S134-S142.
11. Titze J, Machnik A. Sodium sensing in the interstitium and the relationship to hypertension. Curr Opin Nephrol Hypertens. 2010;19:385-62.
12. Campese VM. Salt-sensitive hypertension: renal and cardiovascular implications. Nutr Metab Cardiovasc Dis. 1999;9:143-56.
13. Adrogué HJ, Madias NE. Sodium and potassium in the pathogenesis of hypertension. N Engl J Med. 2007;356:1966-78.
14. Intersalt Cooperative Research Group. Intersalt: an international study of electrolyte excretion and blood pressure. Results for 24 hour urinary sodium and potassium excretion. BMJ. 1988;297(6644):319-28.
15. • Graudal NA, Hubeck-Graudal T, Jürgens G. Effects of low-sodium diet vs. high-sodium diet on blood pressure, renin, aldosterone, catecholamines, cholesterol, and triglyceride (Cochrane Review). Am J Hypertens. 2012;25:1-15. A recent meta-analysis of low- versus high-sodium diets, included 167 studies. In White hypertensive patients and normotensive subjects, blood pressure on the sodium restricted diet decreased by 5.48 mm Hg systolic (p<0.0001) and 2.75 mm Hg for diastolic (p<0.00001) and by 1.27 mm Hg systolic (p=0.0001) and 0.05 mm Hg diastolic (p=0.85), respectively. The average trial duration was 4 weeks. Sodium reduction resulted in significant increases (p<0.001) in renin, aldosterone, noradrenaline, adrenaline, cholesterol, and triglyceride.
16. • Stolarz-Skrzypek K, Kuznetsova T, Thijs L, Tikhonoff V, Seidlerová J, Richart T, et al. Fatal and nonfatal outcomes, incidence of hypertension and blood pressure changes in relation to urinary sodium excretion in White Europeans. JAMA. 2011;305:1777-85. A longitudinal population-based study included 3681 people without cardiovascular disease at baseline, all White Europeans, who were members of families randomly enrolled in the FLEMENGHO or in the EPOGH studies. During a median follow up of 7.9 years, cardiovascular deaths decreased across increasing tertiles of 24-hour sodium excretion. This significant inverse association between cardiovascular mortality and tertile of sodium excretion was retained in multivariable analyses (p for trend =0.02), with a HR of 1.56 in the low tertile versus the overall risk in the whole study population (p=0.04). The 24-hour sodium excretion at baseline did not predict either total mortality or fatal combined with nonfatal cardiovascular events. In a subgroup of 1499 participants who had both blood pressure and sodium excretion measured at baseline and at last follow-up and who were followed up for a median of 6.1 years, in multivariable-adjusted analyses of individual participants, a 100-mmol increment in 24-hour sodium excretion was associated with a significant 1.71 mmHg increase in systolic blood pressure (p<0.001), without concomitant change in diastolic blood pressure.
17. Whelton PK, Appel LJ, Espeland MA, Applegate WB, Ettinger Jr WH, Kostis JB, et al. Sodium reduction and weight loss in the treatment of hypertension in older persons. A randomized controlled trial of nonpharmacologic interventions in the elderly (TONE). JAMA. 1998;279:839-46.
18. Grobbee DE, Hofman A. Does sodium restriction lower blood pressure? BMJ. 1986;293:27-9.
19. Midgley JP, Matthew AG, Greenwood CMT, Logan AG. Effect of reduced dietary sodium on blood pressure. A meta-analysis of randomized controlled trials. JAMA. 1996;275:1590-7.
20. Cutler JA, Follmann DF, Allender PS. Randomized trials of sodium reduction: an overview. Am J Clin Nutr. 1997;65(suppl):643S-51S.
21. He FJ, MacGregor GA. Effect of longer-term modest salt reduction on blood pressure. Cochrane Database Syst Rev. 2004; Issue 3. Art. No.: CD004937.
22. He J, Whelton PK, Appel LJ, Charleston J, Klag MJ. Long-term effects of weight loss and dietary sodium reduction on incidence of hypertension. Hypertension. 2000;35(2):544-9.
23. Chien KL, Hsu HC, Chen PC, Su TC, Chang WT, Chen MF, et al. Urinary sodium and potassium excretion and risk of hypertension in Chinese: report from a community-based cohort study in Taiwan. J Hypertens. 2008;26(9):1750-6.
24. Alderman MH, Madhavan S, Cohen H, Sealey JE, Laragh JH. Low urinary sodium is associated with greater risk of myocardial infarction among treated hypertensive men. Hypertension. 1995;25(6):1144-52.
25. Tunstall-Pedoe H, Woodward M, Tavendale R, A'Brook R, McCluskey MK. Comparison of the prediction by 27 different factors of coronary heart disease and death in men and woman of the Scottish Heart Health Study: cohort study. BMJ. 1997;315(7110):722-9.
26. Tuomilehto J, Jousilahti P, Rastenyte D, Moitchanov V, Tanskanen A, Pietinen P, et al. Urinary sodium excretion and cardiovascular mortality in Finland: a prospective study. Lancet. 2001;357(9259):848-51.
27. Cook NR, Cutler JA, Obarzanek E, Buring JE, Rexrode KM, Kumanyika SK, et al. Long term effects of dietary sodium reduction on cardiovascular disease outcomes: observational follow-up of the trials of hypertension prevention (TOHP). BMJ. 2007;334(7599):885-8.
28. Cook NR, Obarzanek E, Cutler JA, Buring JE, Rexrode KM, Kumanyika SK, et al. Joint effects of sodium and potassium intake on subsequent cardiovascular disease: the Trials of Hypertension Prevention (TOHP) follow-up study. Arch Intern Med. 2009;169:32-40.
29. Staessen JA, Wang JG, Brand E, Barlassina C, Birkenhäger WH, Herrmann SM, et al. Effects of three candidate genes on prevalence and incidence of hypertension in a Caucasian population. J Hypertens. 2001;19(8):1349-58.
30. Kuznetsova T, Staessen JA, Kawecka-Jaszcz K, Babeanu S, Casiglia E, Filipovský J, et al. Quality control of the blood pressure phenotype in the European Project on Genes in Hypertension. Blood Press Monit. 2002;7:215-24.
31. Thomas MC, Moran J, Forsblom C, Harjutsalo V, Thorn L, Ahola A, et al. The association between dietary sodium intake, ESRD, and all-cause mortality in patients with type 1 diabetes. Diabet Care. 2011;34:861-6.
32. Ekinci EL, Clarke S, Thomas MC, Moran JL, Cheong K, MacIsaac RJ, et al. Dietary salt intake and mortality in patients with type 2 diabetes. Diabet Care. 2011;34:703-9.
33. Kagan A, Popper JS, Rhoads GG, Yano K. Dietary and other risk factors for stroke in Hawaiian Japanese men. Stroke. 1985;16(3):390-6.
34. He J, Ogden LG, Vupputuri S, Bazzano LA, Loria C, Whelton PK. Dietary sodium intake and subsequent risk of cardiovascular disease in overweight adults. JAMA. 1999;282(21):2027-34.
35. Alderman MH, Cohen H, Madhavan S. Dietary sodium intake and mortality: the National Health and Nutrition Examination Survey (NHANES I). Lancet. 1998;351(9105):781-5.
36. Cohen HW, Hailpern SM, Alderman MH. Sodium intake and mortality follow-up in the Third National Health and Nutrition Examination Survey (NHANES III). J Gen Intern Med. 2008;23(9):1297-302.
37. Cohen HW, Hailpern SM, Fang J, Alderman MH. Sodium intake and mortality in the NHANES II follow-up study. Am J Med. 2006;119:275.e7-275.e14.
38. Geleijnse JM, Witteman JCM, Stijnen T, Kloos MW, Hofman A, Grobbee DE. Sodium and potassium intake and risk of cardiovascular events and all-cause mortality: the Rotterdam study. Eur J Epidemiol. 2007;22(11):763-70.
39. Umesawa M, Iso H, Date C, Yamamoto A, Toyoshima H, Watanabe Y, et al. Relations between dietary sodium and potassium intakes and mortality from cardiovascular disease: the Japan Collaborative Cohort Study for Evaluation of Cancer Risks. Am J Clin Nutr. 2008;88(1):195-202.
40. Yang Q, Liu T, Kuklina E, Flanders D, Hong Y, Gillespie C, et al. Sodium and potassium intake and mortality among US adults. Arch Intern Med. 2011;171:1183-91.
41. •• O'Donnell MJ, Yusuf S, Mente A, Gao P, Mann JF, Teo K, et al. Urinary sodium and potassium excretion and risk of cardiovascular events. JAMA. 2011;306:2229-38. An observational analysis of two cohorts of high-risk patients (n=28,880) included in the ONTARGET and the TRANSCEND trials. The 24-hour urinary sodium and potassium excretion was estimated from a morning fasting urine sample. The association between cardiovascular outcomes and salt intake had a J shape with a nadir at 4 to 5.99 g per day; a sodium excretion of greater than 7 g per day was associated with increased risk of all cardiovascular events, whereas a sodium excretion of less than 3 g per day was associated with increased cardiovascular mortality and hospitalisation for congestive heart failure.
42. Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358:1547-59.
43. Yusuf S, Teo K, Anderson C, Pogue J, Dyal L, Copland I, et al. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular eventsin high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet. 2008;372:1174-83.
44. •• Taylor RS, Ashton KE, Moxham T, Hooper L, Ebrahim S. Reduced dietary salt for the prevention of cardiovascular disease: a meta-analysis of randomized controlled trials (Cochrane Review). Am J Hypertens. 2011. doi: 10.1038/ajh.2011.115:1-10. A quantitative review of seven randomised clinical trials that addressed the effect of restricting salt intake on cardiovascular disease: three in normotensive volunteers, two in hypertensive patients, one in a mixed population of normo- and hypertensive participants, and one in heart failure. Salt reduction was associated with reductions in urinary salt excretion of between 27 and 39 mmol per 24 hour and reductions in systolic blood pressure between 1 and 4 mm Hg. Pooled relative risks (RRs) comparing the intervention with the reference groups for all-cause mortality were 0.90 (CI, 0.58-1.40; 79 deaths) and 0.96 (CI, 0.83-1.11; 565 deaths) in normotensive and hypertensive participants, respectively. Salt restriction increased the risk of all-cause mortality in patients with heart failure (RR, 2.59; CI, 1.04-6.44; 21 deaths).
45. Strazzullo P, D'Elia L, Kandala NB, Cappuccio FP. Salt intake, stroke, and cardiovascular disease: meta-analysis of prospective studies. BMJ. 2009;339:b4567.
46. Grassi G, Dell'Oro R, Seravalle G, Foglia G, Trevano FQ, Mancia G. Short- and long-term neuroadrenergic effects of moderate dietary sodium restriction in essential hypertension. Circulation. 2002;106:1957-61.
47. Garg K, Williams GH, Hurwitz S, Brown NJ, Hopkins PN, Adler GK. Low-salt diet increases insulin resistance in healthy subjects. Metabolism. 2011;60:965-8.
48. Alderman MH, Madhavan S, Ooi WL, Cohen H, Sealey JE, Laragh JH. Association of the renin-sodium profile with the risk of myocardial infarction in patients with hypertension. N Engl J Med. 1991;324:1098-104.
49. Appel LJ, Frohlich ED, Hall JE, Pearson TA, Sacco RL, Seals DR, et al. The importance of population-wide sodium reduction as a means to prevent cardiovascular disease and stroke. A call to action from the American Heart Association. Circulation. 2011;123:1138-43.
50. Staessen J, Bulpitt CJ, Fagard R, Joossens JV, Lijnen P, Amery A. Salt intake and blood pressure in the general population: a controlled intervention trial in two towns. J Hypertens. 1988;6:965-73.
51. Staessen JA, Lijnen P, Thijs L, Fagard R. Salt and blood pressure in community-based intervention trials. Am J Clin Nutr. 1997;65(suppl):661S-70S.
52. Palar K, Sturm R. Potential societal savings from reduced sodium consumption in the U.S. adult population. Am J Health Promot. 2009;24:49-57.
53. Smith-Spangler CM, Juusola JL, Enns EA, Owens DK, Garber AM. Population strategies to decrease sodium intake and the burden of cardiovascular disease. A cost-effectiveness analysis. Ann Intern Med. 2010;152(8):481-7.
54. Bibbins-Domingo K, Chertow GM, Coxson PG, Moran A, Lightwood JM, Pletcher MJ, et al. Projected effect of dietary salt reductions on future cardiovascular disease. N Engl J Med. 2010;362(7):590-9.
55. Staessen J, Bulpitt C, Fagard R, Joossens JV, Lijnen P, Amery A. Four urinary cations and blood pressure. A population study in two Belgian towns. Am J Epidemiol. 1983;117(6):676-87.
56. Smith WCS, Crombie IK, Tavendale RT, Gulland SK, Tunstall-Pedoe HD. Urinary electrolyte excretion, alcohol consumption, and blood pressure in the Scottish heart health study. BMJ. 1988;297:329-30.
57. Giebisch G. Renal potassium transport: mechanisms and regulation. Am J Physiol. 1998;274:F817-33.
58. Agarwal R, Afzalpurkar R, Fordtran JS. Pathophysiology of potassium absorption and secretion by the human intestine. Gastroenterology. 1994;107:548-71.
59. Zhou MS, Kosaka H, Yoneyama H. Potassium augments vascular relaxation mediated by nitric oxide in the carotid arteries of hypertensive Dahl rats. Am J Hypertens. 2000;13:666-72.
60. Cappuccio FP, MacGregor GA. Does potassium supplementation lower blood pressure ? A meta-analysis of published trials. J Hypertens. 1991;9:465-73.
61. Whelton PK, He J, Cutler JA, Brancati FL, Appel LJ, Follmann D, et al. Effects of oral potassium on blood pressure. Meta-analysis of randomized controlled clinical trials. JAMA. 1997;277:1624-32.
62. Geleijnse JM, Kok FJ, Grobbee DE. Blood pressure response to changes in sodium and potassium intake: a metaregression analysis of randomised trials. J Hum Hypertens. 2003;17:471-80.
63. Appel LJ, Brands MW, Daniels SR, Karanja N, Elmer PJ, Sacks FM, et al. Dietary approaches to prevent and treat hypertension: a scientific statement from the American Heart Association. Hypertension. 2006;47:296-308.